MPH MITTELSTAENDISCHE PHARMA HOLDING AG August 29, 2014
MPH Mittelständische Pharma Holding AG: 1st half-year 2014: sales of EUR 117.6 million (+4.6 % sales growth; net profit of EUR 4.5 million (+7.5 % profit growth)
In the first half of 2014 MPH Group achieved sales of EUR 117.6 million (prior-year period: EUR 112.4 million) and thus an increase of 4.6 % compared to the same period of the previous year. Net income amounted to EUR 4.5 million (prior-year period: EUR 4.2 million), which corresponds to a growth of 7.5 % in comparison with the prior-year period.
For detailed information please refer to our half-year report 2014.
The company MPH Mittelständische Pharma Holding AG, based in Berlin, has strategically concentrated its activities on the growth segments of the healthcare market and is aimed to make a contribution towards cutting costs in the healthcare system.
The focus lies on medicines manufactured on the basis of patent-free and patent-protected active substances for the therapy of chronic diseases. Complementary, services for individual patient therapies, aesthetic surgeries and other medical treatments are offered along the value-added-chain in the healthcare market.
MPH Mittelständische Pharma Holding AG is listed in the Entry Standard
(Open Market) of the Frankfurt stock exchange.
Key figures for the share of MPH Mittelständische Pharma Holding AG: Subscribed capital: EUR 42,813,842.00.
MPH Mittelständische Pharma Holding AG Linda Reichelt
Fasanenstraße 77 Phone.: +49 (0)30 897 30 86 60 E-Mail: ir@mph-ag.de
D-10623 Berlin Fax: +49 (0)30 897 30 86 69 Web: www.mph-ag.de
|
distributed by
|
